Companies
Tropic Biosciences
non-browning and extended-shelf-life banana varieties commercially launched 2025; US/Canada consumer launch 2026; TR4-resistant banana targeting 2027; approvals in Philippines, Colombia, Honduras, US and Canada.
- Country
- United Kingdom
CRISPR
EU
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| crop-biotech | ✓ | ✓ | ✓ | ✓ |
Regulatorsusda-aphisefsamoa-china
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $105 million Series C (2026) | agfundernews.com · thenextweb.com · tropic.bio |
| Production site | mother plantation (established 2025) | agfundernews.com · tropic.bio |
| Regulatory approval | 11 countries including Japan, Brazil, Philippines, USA, Canada, Colombia, Honduras | tropic.bio · freshfruitportal.com · fruitnet.com |
| Headcount | 157 (as of 2024-12-31) | pomanda.com |
| Revenue | GBP 1,073,501 (2024 turnover) medium confidence | pomanda.com |
Independent sources: agfundernews.com · freshfruitportal.com · fruitnet.com · pomanda.com · thenextweb.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Precision Plant Breeding & CRISPR Crop Editing | crop-biotech | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.